TY  - THES
N2  - The development of cystic fibrosis-related diabetes may negatively affect lung health, nutrition and growth status, and mental health of individuals with cystic fibrosis. In this retrospective medical record review study, we will assess changes in glycemic status before and after initiating Trikafta® modulator therapy by utilizing biochemical indicators of glucose homeostasis (hemoglobin A1C, oral glucose tolerance test (OGTT), fasting glucose). We will also assess changes in body mass index (BMI) and lung function (pFEV1) in relation to initiation of Trikafta®. Following analysis of changes within categories, we will then investigate associations between lung function, anthropometrics, and glycemic status to understand the interrelationships between these components of health. The overall goal of this study is to assess the long-term effects of Trikafta® on glycemic status in pediatric patients (ages 11-21 years) with cystic fibrosis.
DO  - 10.6083/v405sb22w
DO  - DOI
AB  - The development of cystic fibrosis-related diabetes may negatively affect lung health, nutrition and growth status, and mental health of individuals with cystic fibrosis. In this retrospective medical record review study, we will assess changes in glycemic status before and after initiating Trikafta® modulator therapy by utilizing biochemical indicators of glucose homeostasis (hemoglobin A1C, oral glucose tolerance test (OGTT), fasting glucose). We will also assess changes in body mass index (BMI) and lung function (pFEV1) in relation to initiation of Trikafta®. Following analysis of changes within categories, we will then investigate associations between lung function, anthropometrics, and glycemic status to understand the interrelationships between these components of health. The overall goal of this study is to assess the long-term effects of Trikafta® on glycemic status in pediatric patients (ages 11-21 years) with cystic fibrosis.
T1  - Trikafta® modulator therapy and glycemic status in pediatric patients with cystic fibrosis
DA  - 2022
AU  - Merrill, Courtney
L1  - https://digitalcollections.ohsu.edu/record/9970/files/Merrill.Courtney.2022.pdf
PB  - Oregon Health and Science University
PY  - 2022
ID  - 9970
L4  - https://digitalcollections.ohsu.edu/record/9970/files/Merrill.Courtney.2022.pdf
KW  - Child
KW  - Adolescent
KW  - Glucose Tolerance Test
KW  -  Cystic Fibrosis
KW  - Diabetes Mellitus
KW  -  Glycated Hemoglobin
KW  - trikafta
TI  - Trikafta® modulator therapy and glycemic status in pediatric patients with cystic fibrosis
Y1  - 2022
L2  - https://digitalcollections.ohsu.edu/record/9970/files/Merrill.Courtney.2022.pdf
LK  - https://digitalcollections.ohsu.edu/record/9970/files/Merrill.Courtney.2022.pdf
UR  - https://digitalcollections.ohsu.edu/record/9970/files/Merrill.Courtney.2022.pdf
ER  -